Evercore ISI Downgrades Chinook Therapeutics (KDNY) to In Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KDNY Hot Sheet
Price: $40.39 --0%
Rating Summary:
2 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
2 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Evercore ISI analyst Josh Schimmer downgraded Chinook Therapeutics (NASDAQ: KDNY) from Outperform to In Line with a price target of $40.00 (from $30.00).
For an analyst ratings summary and ratings history on Chinook Therapeutics click here. For more ratings news on Chinook Therapeutics click here.
Shares of Chinook Therapeutics closed at $37.87 yesterday.
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- Kraft Heinz Company (KHC) PT Raised to $24 at Jefferies
- Matador (MTDR) PT Raised to $66 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
